Pancreatic Cancer Research

ResearcherThe University of Texas Health Science Center at HoustonActive in the last 2 years

Nirav C Thosani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4607-6241; OpenAlex author ID A5008651395; NIH RePORTER profile ID 15123777. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 1, last author 4)
Trials
4 (principal investigator on 4)
Grants
1
Labs led
1
Collaborators
68
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 trial · 2016: 1 paper · 2017: none · 2018: 1 trial · 2019: none · 2020: none · 2021: 3 papers, 1 trial · 2022: 4 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers, 1 trial, 1 grant

Papers 18

  1. Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer Co-author DOI 10.64898/2026.04.05.713683↗
  2. Pulsed Field Ablation Enables Stromal Manipulation and Tumor Reduction in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.64898/2026.10.06.756887↗
  3. Endoscopic Immuno-Oncology: A New Frontier in Treatment of Pancreatic Cancer. Last author DOI 10.3390/cancers17132091↗
  4. EUS-guided radiofrequency ablation for pancreatic adenocarcinoma. Last author DOI 10.1016/j.gie.2024.04.2926↗
  5. Endoscopic innovations in diagnosis and management of pancreatic cancer: a narrative review and future directions. Last author DOI 10.1177/17562848241297434↗
  6. Lifestyle Medicine for the Prevention and Treatment of Pancreatitis and Pancreatic Cancer. Co-author DOI 10.3390/diagnostics14060614↗
  7. Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodu… Last author DOI 10.37349/etat.2024.00263↗
  8. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2553↗
  9. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-22-0379↗
  10. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations Co-author DOI 10.1016/j.gie.2021.12.001↗
  11. American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review… Co-author DOI 10.1016/j.gie.2021.12.002↗
  12. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  13. Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ducta… Co-author DOI 10.3389/fonc.2022.995027↗
  14. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Co-author DOI 10.1038/s41374-020-00490-5↗
  15. Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer Co-author DOI 10.1038/s41374-021-00615-4↗
  16. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine Co-author DOI 10.1101/2021.11.29.470415↗
  17. Increased Incidence of Second Primary Pancreatic Cancer in Patients with Prior Colorectal Cancer: A Population-Based US Study. Co-author DOI 10.1007/s10620-016-4170-x↗
  18. Pancreatic Cancer Screening: What We Do and Do Not Know First author DOI 10.1016/j.cgh.2013.02.004↗

Trials 4

  1. Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions Principal investigator NCT07737171↗
  2. EUS-RFA PANCARDINAL-1 Trial Principal investigator NCT04990609↗
  3. Safety and Efficacy of EUS-RFA in the Treatment of Pancreatic Lesions: A Prospective Registry Principal investigator NCT07136324↗
  4. Comparison Of Radiation Exposure To Patients During Endoscopic Retrograde Cholangiopancreatography (ERCP) Performed By Endoscopists Trained In Judicious Use Of… Principal investigator NCT03525353↗

Grants 1

  1. A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radi… R01CA277161↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer M. Bailey · 11 shared papers, 2021–2026 · strength 2.08
  2. Curtis Jackson Wray · 7 shared papers, 2021–2026 · strength 1.30
  3. Jennifer Bailey Lundberg · 1 shared grant, 2026 · strength 1.26
  4. Lincoln N. Strickland · 5 shared papers, 2022–2026 · strength 0.97
  5. Erika Yanil Faraoni · 5 shared papers, 2021–2024 · strength 0.76
  6. Putao Cen · 3 shared papers, 2023–2026 · strength 0.61
  7. Prateek Suresh Harne · 2 shared papers, 2024 · strength 0.59
  8. Urvinder Kaur Sardarni · 2 shared papers, 2026 · strength 0.52
  9. Khadija Shahab Turabi · 2 shared papers, 2026 · strength 0.52
  10. MacKenzie V. Demmel · 2 shared papers, 2026 · strength 0.52
  11. Kanchan Singh · 4 shared papers, 2021–2023 · strength 0.46
  12. Florencia M. McAllister · 4 shared papers, 2021–2023 · strength 0.46
  13. Varun Vemulapalli MDi · 1 shared paper, 2025 · strength 0.42
  14. Sushovan Guha · 4 shared papers, 2013–2021 · strength 0.37
  15. Marcia Irene Canto · 3 shared papers, 2022 · strength 0.34
  16. Elena M. Stoffel · 3 shared papers, 2022 · strength 0.34
  17. Kyle L. McAndrews · 1 shared paper, 2026 · strength 0.29
  18. Sruthi Kapliyil Subramanian · 1 shared paper, 2024 · strength 0.28
  19. Vishali Moond · 1 shared paper, 2024 · strength 0.28
  20. Bhaumik S. Brahmbhatt · 1 shared paper, 2024 · strength 0.28
  21. Pritesh R. Mutha · 1 shared paper, 2024 · strength 0.28
  22. Mamoun Younes · 2 shared papers, 2021 · strength 0.24
  23. Anirban Maitra · 2 shared papers, 2021 · strength 0.24
  24. Craig D. Logsdon · 2 shared papers, 2021 · strength 0.24
  25. Charles M. Vollmer · 2 shared papers, 2022 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.